



# Polivy (polatuzumab vedotin-piiq) Medication Precertification Request

Page 1 of 2

(All fields must be completed and legible for Precertification Review.)

Aetna Precertification Notification  
503 Sunport Lane, Orlando, FL 32809

Phone: 1-866-752-7021  
FAX: 1-888-267-3277

For Medicare Advantage Part B:

Phone: 1-866-503-0857  
FAX: 1-844-268-7263

Please indicate:  Start of treatment: Start date \_\_\_\_/\_\_\_\_/\_\_\_\_  
 Continuation of therapy: Date of last treatment \_\_\_\_/\_\_\_\_/\_\_\_\_

Precertification Requested By: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_

### A. PATIENT INFORMATION

First Name:		Last Name:		DOB:	
Address:		City:		State: ZIP:	
Home Phone:		Work Phone:		Cell Phone:	
E-mail:		Patient Current Weight: _____ lbs or _____ kgs		Patient Height: _____ inches or _____ cms	
Allergies:					

### B. INSURANCE INFORMATION

Aetna Member ID #: _____		Does patient have other coverage? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Group #: _____		If yes, provide ID#: _____ Carrier Name: _____	
Insured: _____		Insured: _____	
Medicare: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____		Medicaid: <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, provide ID #: _____	

### C. PRESCRIBER INFORMATION

First Name:		Last Name:		(Check One): <input type="checkbox"/> M.D. <input type="checkbox"/> D.O. <input type="checkbox"/> N.P. <input type="checkbox"/> P.A.	
Address:		City:		State: ZIP:	
Phone:		Fax:		St Lic #: NPI #: DEA #: UPIN:	
Provider E-mail:		Office Contact Name:		Phone:	

Specialty (Check one):  Oncologist  Internist  Other: \_\_\_\_\_

### D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

<b>Place of Administration:</b>		<b>Dispensing Provider/Pharmacy:</b> <i>Patient Selected choice</i>	
<input type="checkbox"/> Self-administered <input type="checkbox"/> Physician's Office		<input type="checkbox"/> Physician's Office <input type="checkbox"/> Retail Pharmacy	
<input type="checkbox"/> Outpatient Infusion Center Phone: _____		<input type="checkbox"/> Specialty Pharmacy <input type="checkbox"/> Mail Order	
Center Name: _____		<input type="checkbox"/> Other: _____	
<input type="checkbox"/> Home Infusion Center Phone: _____		Name: _____	
Agency Name: _____		Phone: _____ Fax: _____	
<input type="checkbox"/> Administration code(s) (CPT): _____		Address: _____	
Address: _____		TIN: _____ PIN: _____	

### E. PRODUCT INFORMATION

Request is for  Polivy (polatuzumab vedotin-piiq): Dose: \_\_\_\_\_ Frequency: \_\_\_\_\_

### F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: \_\_\_\_\_ Secondary ICD Code: \_\_\_\_\_ Other ICD Code: \_\_\_\_\_

### G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

#### For All Requests (clinical documentation required):

Please indicate the patient's documented diagnosis:  Diffuse large B-cell lymphoma  
 High grade B-cell lymphoma  
 Yes  No Does the patient have translocations of MYC and BCL2 and/or BCL6 as detected by FISH or standard cytogenetics?  
 Other-Please explain: \_\_\_\_\_

Please indicate how many cycles of chemotherapy containing Polivy (polatuzumab vedotin-piiq) are planned: \_\_\_\_\_

Yes  No Will Polivy (polatuzumab vedotin-piiq) be used as second-line or subsequent therapy?  
 Second-line therapy  Subsequent therapy

Yes  No Has the patient received at least two prior therapies?  
Please indicate the response to the previous therapies:  Partial response  No response  Disease relapsed  
 Disease is refractory  Disease progression  
 None of the above

Yes  No Will Polivy (polatuzumab vedotin-piiq) be used in combination with bendamustine and a rituximab product?  
 Yes  No Is the patient a candidate for transplant?

#### For Continuation of therapy requests (clinical documentation required for all requests):

Yes  No How many cycles of Polivy (polatuzumab vedotin-piiq) has the patient received in a lifetime? \_\_\_\_\_  
 Yes  No Has the patient experienced disease progression?  
 Yes  No Has the patient experienced unacceptable toxicity?

Continued on next page



# Polivy (polatuzumab vedotin-piiq) Medication Precertification Request

Page 2 of 2

(All fields must be completed and legible for Precertification Review.)

**Aetna Precertification Notification**  
503 Sunport Lane, Orlando, FL 32809  
**Phone:** 1-866-752-7021  
**FAX:** 1-888-267-3277

**For Medicare Advantage Part B:**  
**Phone:** 1-866-503-0857  
**FAX:** 1-844-268-7263

Patient First Name	Patient Last Name	Patient Phone	Patient DOB
--------------------	-------------------	---------------	-------------

## H. ACKNOWLEDGEMENT

**Request Completed By (Signature Required):** \_\_\_\_\_ **Date:** \_\_\_\_ / \_\_\_\_ / \_\_\_\_

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.